Theranos case highlights the challenges in venture capital
The collapse of Theranos and the subsequent travails of its founder, Elizabeth Holmes, may well have cooled somewhat the formerly white-hot search of venture capitalists for the next great high-tech unicorn.
After the verdict, Bijan Salehizadeh, holder of an MD from the Columbia University College of Physicians and Surgeons (1999), and an investor at Highland Capital Partners, reminisced for The New York Times about his reluctance to invest in Theranos in its early years, and how he came to question that judgment while listening to the venture capitalists hanging out at the Rosewood . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.
